CATALYST PHARMACEUTICALS, INC. Contracts & Agreements

License, Supply and Commercialization Agreement between the Company and KYE Pharmaceuticals, Inc., dated as of July 23, 2024 (Filed With SEC on August 7, 2024)

Offer Letter between the Company and Richard J. Daly (Filed With SEC on February 28, 2024)

Offer Letter between the Company and Michael W. Kalb (Filed With SEC on February 28, 2024)

Separation Agreement between the Company and Patrick J. McEnany (Filed With SEC on February 28, 2024)

Separation Agreement between the Company and Alicia Grande (Filed With SEC on February 28, 2024)

Severance and Change in Control Plan (Filed With SEC on February 28, 2024)

Underwriting Agreement dated January 4, 2024, between Catalyst Pharmaceuticals, Inc. and BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the... (Filed With SEC on January 5, 2024)

Amendment to Transition Services Agreement between Eisai Inc., a subsidiary of Eisai and the Company, dated as of July 31, 2023 (certain identified information has been excluded... (Filed With SEC on August 9, 2023)

Amendment to the Investment Agreement, dated as of July 18, 2023, between Santhera and the Company (Filed With SEC on July 21, 2023)

License and Collaboration Agreement, executed and delivered as of June 19, 2023, by and between Santhera, its wholly-owned subsidiary, Santhera Pharmaceuticals (Schweiz) AG, and... (Filed With SEC on June 23, 2023)

Investment Agreement, dated as of June 19, 2023, by and between Santhera and the Company (certain identified information has been excluded from the exhibit because it both (i) is... (Filed With SEC on June 23, 2023)

Asset Purchase Agreement by and between Eisai and the Company, dated as of December 17, 2022 (certain identified information has been excluded from the exhibit because it both (i)... (Filed With SEC on December 22, 2022)

Form of Transition Services Agreement between Eisai, Inc., a subsidiary of Eisai, and the Company (certain identified information has been excluded from the exhibit because it... (Filed With SEC on December 22, 2022)

Form of Supply Agreement between Eisai and the Company (certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) would be... (Filed With SEC on December 22, 2022)

Amendment No. 8 to Employment Agreement between the Company and Patrick J. McEnany, dated September 8, 2022 (Filed With SEC on September 9, 2022)

License and Asset Purchase Agreement, dated as of July 11, 2022, by and between Jacobus Pharmaceutical Company, Inc. and the Company (Filed With SEC on July 12, 2022)

Settlement Agreement, dated July 11, 2022, by and between the Company and SERB SA, on the one hand, and Jacobus Pharmaceutical Company Inc., PantherRx Specialty LLC, and Panther... (Filed With SEC on July 12, 2022)

Description of the Companys Capital Stock (Filed With SEC on March 16, 2022)

License & Supply Agreement, dated as of June 28, 2021, between DyDo Pharma, Inc. and the Company (Certain identified information has been excluded from the exhibit because it both... (Filed With SEC on June 30, 2021)

Description of the Companys Capital Stock (Filed With SEC on March 15, 2021)

Amendment No. 7 to Employment Agreement between the Company and Patrick J. McEnany, dated September 9, 2020 (Filed With SEC on September 11, 2020)

License & Supply Agreement, dated as of August 14, 2020, between KYE Pharmaceuticals, Inc. and the Company (Certain identified information has been excluded from the exhibit... (Filed With SEC on August 20, 2020)

Fifth Amendment to Lease Agreement, dated effective as of May 7, 2020, among the Company and PRII 355 Alhambra Circle, LLC (Certain identified information has been excluded from... (Filed With SEC on May 13, 2020)

Description of the Companys Capital Stock (Filed With SEC on March 16, 2020)

Amendment No. 2 to Rights Agreement, dated as of August 28, 2019, between Catalyst Pharmaceuticals, Inc. and Continental Stock Transfer and Trust Company, as Rights Agent (Filed With SEC on August 30, 2019)

Amendment No. 2 to License Agreement, made and entered into effective as of May 29, 2019, by and between BioMarin and the Company (certain identified information has been excluded... (Filed With SEC on May 30, 2019)

Amendment No. 1 to Collaborative Agreement with Endo for generic Sabril (certain identified information has been excluded from this exhibit because it is both (i) not material and... (Filed With SEC on May 10, 2019)

Development, License and Commercialization Agreement by and between the Company and Endo Ventures Limited, dated as of December 18, 2018 (portions of this exhibit have been... (Filed With SEC on December 26, 2018)

Fourth Amendment to Lease, dated effective as of August 13, 2018, between the Company and PRII 355 Alhambra Circle, LLC (portions of this exhibit have been omitted and filed... (Filed With SEC on August 17, 2018)

Settlement Agreement, effective as of July 26, 2018, among the Company, BioMarin Pharmaceutical Inc. and Aceras BioMedical LLC, in its capacity as stockholder representative for... (Filed With SEC on August 7, 2018)

Amendment No. 6 to Employment Agreement between the Company and Patrick J. McEnany, dated May 25, 2018 (Filed With SEC on May 31, 2018)

Underwriting Agreement, dated November 28, 2017, between Catalyst Pharmaceuticals, Inc. and Piper Jaffray & Co., as representative of the underwriters named in Schedule I thereto (Filed With SEC on November 28, 2017)

AMENDMENT NO. 1 TO RIGHTS AGREEMENT (Filed With SEC on September 20, 2016)

FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on June 24, 2016)

CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 THIRD AMENDMENT TO LEASE (Filed With SEC on August 7, 2015)

CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 THIRD AMENDMENT TO LEASE (Filed With SEC on March 27, 2015)

10,000,000 Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITINGAGREEMENT (Filed With SEC on February 4, 2015)

CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by [****]1 AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on April 17, 2014)

13,023,750 Shares CatalystPharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 3, 2014)

CATALYST PHARMACEUTICAL PARTNERS, INC. 2014 STOCK INCENTIVE PLAN (Filed With SEC on March 4, 2014)

SECOND AMENDMENT TO LEASE (Filed With SEC on February 20, 2014)

TERMINATION AGREEMENT (Filed With SEC on November 13, 2013)

[To be separately provided to the Investor] (Filed With SEC on September 5, 2013)

CATALYST PHARMACEUTICAL PARTNERS, INC. 8,800,000 shares of Common Stock PLACEMENT AGENT AGREEMENT (Filed With SEC on September 5, 2013)

FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on August 29, 2013)

CONFIDENTIAL TREATMENT REQUESTED Redacted portions are indicated by[****]1 LICENSE AGREEMENT (Filed With SEC on January 4, 2013)

CONVERTIBLE PROMISSORY NOTE AND NOTE PURCHASE AGREEMENT (Filed With SEC on October 31, 2012)

CONFIDENTIAL TREATMENT REQUESTED Redactedportions are indicated by [****]1 LICENSE AGREEMENT (Filed With SEC on October 31, 2012)

[To be separately provided to the Investor] (Filed With SEC on August 28, 2012)

CATALYST PHARMACEUTICAL PARTNERS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on August 28, 2012)

CATALYST PHARMACEUTICAL PARTNERS, INC. 4,000,000 shares of Common Stock and Warrants to purchase up to 1,200,000 shares of Common Stock PLACEMENTAGENT AGREEMENT (Filed With SEC on August 28, 2012)

6,000,000 Shares Warrants to Purchase 6,000,000 Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on May 29, 2012)

CATALYST PHARMACEUTICAL PARTNERS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on May 4, 2012)

[ ] Shares Warrants to Purchase [ ] Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on May 4, 2012)

[ ] Shares Catalyst Pharmaceutical Partners, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 25, 2012)

LICENSE AGREEMENT (Filed With SEC on March 30, 2012)

CATALYST PHARMACEUTICAL PARTNERS, INC. 3,046,740 shares of Common Stock and Warrants to purchase up to 1,523,370 shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on October 28, 2011)

CATALYST PHARMACEUTICAL PARTNERS, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on October 28, 2011)

RIGHTS AGREEMENT between CATALYST PHARMACEUTICAL PARTNERS, INC. and CONTINENTAL STOCK TRANSFER AND TRUST COMPANY as Rights Agent Dated as of September 20, 2011 TABLE OF CONTENTS (Filed With SEC on September 23, 2011)

THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on September 15, 2011)

FIRST AMENDMENT TO LEASE (Filed With SEC on August 15, 2011)

2,259,943 Shares CATALYST PHARMACEUTICAL PARTNERS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 8, 2011)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 6, 2010)

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on November 12, 2009)

Rodman & Renshaw, LLC 1251 Avenue of the Americas, 20th Floor, New York, NY 10020 Tel: 212 ###-###-#### Fax: 212 ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on October 2, 2009)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on October 2, 2009)

LICENSE AGREEMENT (Filed With SEC on September 2, 2009)

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on December 23, 2008)

Catalyst Pharmaceutical Partners, Inc. 355 Alhambra Circle Suite 1370 Coral Gables, Florida 33134 (Filed With SEC on December 23, 2008)

Ex-10.1 Engagement Letter (Filed With SEC on September 12, 2008)

Ex-10.2 Form of Securities Purchase Agreement (Filed With SEC on September 12, 2008)

EX-10.1 Consulting Agreement (Filed With SEC on May 15, 2008)

EX-10.1 Lease Agreement (Filed With SEC on May 14, 2007)

AMENDMENT NO. 1 TO CONSULTING AGREEMENT (Filed With SEC on January 3, 2007)

EX-10.1 Employment Agreement with Patrick McEnany (Filed With SEC on December 15, 2006)

EX-10.2 Employment Agreement with Jack Weinstein (Filed With SEC on December 15, 2006)

EX-10.3 Stock Option Agreement (Filed With SEC on December 15, 2006)

EX-1.1 Form of Underwriting Agreement (Filed With SEC on September 26, 2006)

EX-4.1 Specimen Stock Certificate (Filed With SEC on September 26, 2006)

EX-10.1 Form of Employment Agreement w/Patrick J. McEnany (Filed With SEC on September 26, 2006)

EX-10.2 Form of Employment Agreement w/Jack Weinstein (Filed With SEC on September 26, 2006)

EX-10.11 Consulting Agreement w/Charles O'keefe (Filed With SEC on September 1, 2006)

EX-10.9 Agreement and Plan of Merger (Filed With SEC on September 1, 2006)

EX-10.14 Agreement with Pharmaceutics International Inc (Filed With SEC on September 1, 2006)

EX-10.13 Agreement with Charles Gorodetzky (Filed With SEC on September 1, 2006)

EX-10.12 Agreement with Donald Jasinski (Filed With SEC on September 1, 2006)

EX-10.10 Consulting Agreement as amended/Weinstein (Filed With SEC on September 1, 2006)

EXHIBIT 10.8 STOCK INCENTIVE PLAN (Filed With SEC on July 25, 2006)

EXHIBIT 10.7 STOCK OPTION AGREEMENTS/CHARLES O'KEEFE (Filed With SEC on July 25, 2006)

EXHIBIT 10.6 STOCK OPTION AGREEMENTS/JACK WEINTSTEIN (Filed With SEC on July 25, 2006)

EXHIBIT 10.5 STOCK OPTION AGREEMENTS/HUBERT HUCKEL (Filed With SEC on July 25, 2006)

EXHIBIT 10.4 STOCK OPTION AGREEMENTS/PATRICK J. MCENANY (Filed With SEC on July 25, 2006)

EXHIBIT 10.3 LICENSE AGREEMENT (Filed With SEC on July 25, 2006)

Category

Industry

Companies

Contracts

CATALYST PHARMACEUTICALS, INC. Contracts & Agreements